Dec 29
Current report
8-K
Events of Dec 19
Bankruptcy or receivership, Other events
CLSDQ · Clearside Biomedical, Inc.
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Volume
—
Avg daily vol (3M)
—
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
No Price Data
No daily price data is available for this stock yet. Data syncs automatically.
Latest documents
2025
Dec 8
Current report
8-K
Delisting notice or listing transfer
Nov 25
Current report
8-K
Events of Nov 23
Bankruptcy or receivership, Delisting notice or listing transfer, Regulation FD disclosure
Nov 14
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $201K
▼ 80.6%
Net loss $5.97M
Diluted EPS -$1.14
Oct 7
Current report
8-K
Other events
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$3.33M
Trailing 12 months
Net income (TTM)
−$26.00M
Trailing 12 months
Revenue growth YoY
-80.6%
Year over year
Operating margin
-689.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1,668.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Limited
Market backdrop
VIX 25.6 · fear
Equity put/call 0.59
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
1.83% of shares out · ▬ 0.0% MoM · 18.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Fundamentals
Revenue growth
−80%
Y/Y
EPS growth
+11%
Y/Y
Free cash flow
$-25.7M
Balance sheet
$17.6M
net cash
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLSDQ
this stock
Clearside Biomedical, Inc.
|
$1.30M | — | -79.8% | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$138.71B | +20.7% | +46.2% | 35.2 | 1.7% |
|
MRNA
Moderna, Inc.
|
$96.40B | +762.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$93.82B | +17.2% | +20.8% | 20.1 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.72B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.5%
- Net QoQ
- 0 sh
- Top holder
- DRW Securities, LLC
Held
Float
Short & Settlement
Financials
Filings